RNAC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RNAC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-21), Cartesian Therapeutics's share price is $25.83. Cartesian Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.
The historical rank and industry rank for Cartesian Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:
During the past 10 years, the highest Price-to-Owner-Earnings of Cartesian Therapeutics was 33.97. The lowest was 10.75. And the median was 25.39.
As of today (2024-05-21), Cartesian Therapeutics's share price is $25.83. Cartesian Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-56.10. Therefore, Cartesian Therapeutics's PE Ratio for today is At Loss.
As of today (2024-05-21), Cartesian Therapeutics's share price is $25.83. Cartesian Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-23.13. Therefore, Cartesian Therapeutics's PE Ratio without NRI for today is At Loss.
During the past 10 years, Cartesian Therapeutics's highest PE Ratio without NRI was 246.00. The lowest was 0.00. And the median was 38.75.
The historical data trend for Cartesian Therapeutics's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cartesian Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Owner-Earnings | Get a 7-Day Free Trial | - | 20.30 | - | - | - |
Cartesian Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Price-to-Owner-Earnings | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Cartesian Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Cartesian Therapeutics's Price-to-Owner-Earnings falls into.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Cartesian Therapeutics's Price-to-Owner-Earnings for today is calculated as
Price-to-Owner-Earnings | = | Share Price | / | Owner Earnings per Share (TTM) |
= | 25.83 | / | -48.40 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cartesian Therapeutics (NAS:RNAC) Price-to-Owner-Earnings Explanation
For how to get Owner Earnings per Share (TTM), please click.
Thank you for viewing the detailed overview of Cartesian Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Carsten Brunn | director, officer: President & CEO | C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472 |
Peter G Traber | officer: Chief Medical Officer | 430 THAMER LANE, HOUSTON TX 77025 |
Takashi Kei Kishimoto | officer: Chief Scientific Officer | 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472 |
Lloyd P. Johnston | officer: COO and SVP, R&D | 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472 |
Blaine Davis | officer: Chief Financial Officer | C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014 |
Carrie Smith Cox | director | SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Timothy C Barabe | director | C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803 |
Timothy A Springer | director | 36 WOODMAN ROAD, CHESTNUT HILL MA 02467 |
Kevin Tan | officer: Chief Financial Officer | 20 HICKORY ROAD, WELLESLEY MA 02482 |
Nishan M Desilva | director | 11119 NORTH TORREY PINES RD STE 200, LA JOLLA CA 92037 |
Ann K. Donohue | officer: VP Finance | C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, BUILDING ONE, WATERTOWN MA 02472 |
Bradford D. Dahms | officer: Chief Financial Officer | C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472 |
Goran Ando | director | |
Scott Dunseth Myers | director | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Elona Esq. Kogan | officer: General Counsel | C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-16-2022
By GuruFocusNews GuruFocusNews • 05-02-2022
By Value_Insider Value_Insider • 11-28-2022
By PurpleRose PurpleRose • 07-28-2022
By sperokesalga sperokesalga • 03-21-2023
By Marketwired • 11-03-2023
By Stock market mentor Stock market mentor • 01-09-2023
By PRNewswire • 01-18-2024
By GuruFocusNews GuruFocusNews • 04-04-2022
By PurpleRose PurpleRose • 08-01-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.